Recent laboratory studies have identified a promising antiviral drug, MDL-001, which shows effectiveness against a variety of common viruses, including coronaviruses, respiratory syncytial virus (RSV), norovirus, and multiple strains of influenza and hepatitis. This drug, initially developed for breast cancer treatment under the name ERA-923, was abandoned in the early 2000s due to limited clinical benefits. However, advancements in artificial intelligence (AI) drug discovery have revived interest in its potential antiviral properties.
Researchers at Model Medicines, led by co-founder Daniel Haders, utilized AI to analyze existing chemical and biological data in search of a drug that could inhibit RNA-dependent RNA polymerase, an enzyme crucial for viral replication. The AI identified MDL-001 as a candidate capable of binding to a conserved domain of this enzyme, known as the Thumb-1 domain, which is common across numerous viruses.
Laboratory tests demonstrated that MDL-001 effectively inhibited various viruses, including influenza and coronaviruses, in infected cells. Additionally, in animal models, the drug reduced viral loads in the lungs of mice infected with COVID-19 and alleviated weight loss associated with the illness.
Despite the optimism surrounding MDL-001, some experts express caution. Critics point out that previous attempts to target the Thumb-1 domain have not yielded broad-spectrum antiviral agents. Model Medicines aims to address safety concerns through a forthcoming clinical trial set to commence next year, after which the drug could potentially serve as a multipurpose antiviral treatment for various viral infections and future pandemics.